Osteomalacia
Overview
Darker skin (Fitzpatrick IV-VI) - reduced UVB penetration
Limited sun exposure - housebound, cultural dress
Elderly - reduced skin synthesis
Malabsorption - coeliac disease, IBD
Chronic kidney disease - impaired renal activation
Chronic liver disease - impaired hepatic hydroxylation
Long-term anticonvulsants - accelerated catabolism
Pregnancy and lactation - increased demand
Presentation
•Bone pain - diffuse, dull, aching; spine, pelvis, hips, lower limbs; worse with weight-bearing and direct pressure
•Proximal muscle weakness - characteristic; caused by calcitriol deficiency and impaired calcium-mediated muscle contraction
•Waddling gait - due to proximal lower limb myopathy
•Insufficiency fractures - minimal trauma; femoral neck, pubic rami, ribs, metatarsals
•Features of hypocalcaemia (severe cases) - perioral paraesthesia, tetany, Chvostek's sign, Trousseau's sign
Investigations
•Serum 25-OH vitamin D - primary diagnostic test; low confirms vitamin D deficiency
•Serum calcium - low or low-normal
•Serum phosphate - low (PTH promotes renal phosphate excretion)
•ALP - raised (overactive osteoblasts attempting mineralisation)
•PTH - elevated (secondary hyperparathyroidism)
•Bone X-ray - Looser zones (pseudofractures), generalised demineralisation with 'fuzzy' trabecular pattern
•Renal function and LFTs - identify CKD or liver disease as underlying cause
•DXA scan - low BMD (cannot distinguish from osteoporosis without biochemistry)
•Bone biopsy with tetracycline labelling - gold standard; widened osteoid seams and reduced mineralisation front; rarely required when biochemistry is clear
Management
•Identify and treat underlying cause - gluten-free diet in coeliac, review anticonvulsants, manage CKD-mineral bone disorder
•Loading dose: colecalciferol ~300,000 IU total over 6-10 weeks (weekly or daily doses) - rapidly replenishes stores
•Maintenance: colecalciferol 800-2000 IU daily after loading - combined with dietary and sun exposure advice
•Calcium supplementation - if dietary intake insufficient
🥈 Second-line
•alfacalcidol - used in CKD where renal 1-alpha hydroxylase is impaired; bypasses renal activation step
•Phosphate supplementation - in renal phosphate wasting (X-linked hypophosphataemia, Fanconi syndrome)
Follow-up
•Recheck calcium, phosphate, ALP, PTH, and 25-OH vitamin D at ~3 months to confirm biochemical response
•Bone healing (including Looser zone resolution) typically occurs within 6 months
•Recheck vitamin D levels annually in those on maintenance therapy or with ongoing risk factors